Clinical trial Recruiting at 5 sites Interventional Ages 0 Days to 14 Days

Effects of a supplement with human milk oligosaccharides on feeding in preterm infants

Official title: Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs): A Post-Market Study

Run by Société des Produits Nestlé (SPN) · NCT06212427 · Data updated 2026-11-12

This study tests if a special liquid supplement made from human milk can help preterm infants eat better and grow stronger.

More Respiratory Distress Syndrome in Premature Infant trials

Quick facts

Study typeInterventional
Ages0 Days to 14 Days
SexAll
Enrollment188 (estimated)
SponsorSociété des Produits Nestlé (SPN)
Industry-sponsored
Locations6 sites (Linz and 5 other locations)
StatusRecruiting
StartedNovember 20, 2023
Main results expectedFebruary 28, 2026
Study endsFebruary 28, 2026
Registry record updatedDecember 8, 2025
Trial IDNCT06212427 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are preterm infants born at or below 34 weeks gestational age and weighing less than 2500 grams.

Probably not a fit

Patients who are clinically unstable or have significant health issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of a liquid supplement containing two specific human milk oligosaccharides, 2'-fucosyllactose and lacto-N-neotetraose, on feeding tolerance and growth in preterm infants. The research is conducted in a real-world setting, focusing on infants born at or below 34 weeks gestational age and weighing less than 2500 grams. The study aims to assess how well these infants tolerate feeding and monitor any adverse events associated with the supplement.

Why it matters

Potential benefit: If successful, this study could improve feeding tolerance and growth outcomes for preterm infants.

How similar studies have gone: Other studies have shown promising results with similar approaches using human milk oligosaccharides in preterm infants.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Written informed consent has been obtained from at least one parent (or other legally acceptable representative \[LAR\], if applicable)
2. Infant's parent(s)/LAR is of legal age of majority, has parental authority, must understand the consent form and other relevant study documents, and is willing and able to fulfil the requirements of the study protocol
3. Infant gestational age is ≤ 34 weeks as determined by the first day of the mother's last menstrual period or by fetal ultrasound
4. Infant birth weight ≤ 2500g
5. Infant postnatal age ≤ 14 days
6. Infant has tolerated trophic feeds (e.g., 10-15 mL/kg/day) for at least 24 hours but has not yet reached full enteral feeding

Exclusion Criteria:

1. Infant is clinically unstable, for example:

   1. Infant has hemodynamic instability as evidenced by clinical signs of sepsis, hypotension (MAP \< 5th percentile for age for at least three hours), or is receiving vasopressor drugs
   2. Infant has received an exchange transfusion within the past 48 hours
   3. Infant has had an episode of severe asphyxia at birth (PH less than 7.0)
   4. Infant has signs of necrotizing enterocolitis according to modified Bell staging criteria (stage IIA or higher)
2. Major congenital (e.g., heart disease, skeletal dysplasia, chondrodystrophy, gastrointestinal obstruction or atresia) or chromosomal abnormality (e.g., trisomy 21, Turner syndrome)
3. Infant has other medical condition that, in the judgement of the investigator, would make the child inappropriate for entry into the study
4. Participation in another interventional clinical study that may interfere with the results of this study

Where it's running

  • Kepler Universitätsklinikum Linz
    Linz, Austria
    Recruiting
  • Evangelisches Waldkrankenhaus Spandau
    Berlin-Spandau, Germany
    Recruiting
  • Kinderklinik Darmstadt
    Darmstadt, Germany
    Recruiting
  • Uniklinik Heidelberg
    Heidelberg, Germany
    Recruiting
  • Klinikum Nürnberg
    Nuremberg, Germany
    Recruiting
  • Wilhelmstift Hamburg
    Hamburg, Germany
    Withdrawn

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.